Guger, Michael
,
Enzinger, Christian
Leutmezer, Fritz
Kraus, Jörg
Kalcher, Stefan
Kvas, Erich
Berger, Thomas
Funding for this research was provided by:
Biogen Austria
Novartis Pharma Austria
Genzyme Austria
Article History
Received: 24 May 2019
Revised: 8 July 2019
Accepted: 9 July 2019
First Online: 16 July 2019
Change Date: 17 September 2019
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. First and last names of the authors were interchanged. The correct author names are given below.
Compliance with ethical standards
:
: Michael Guger received support and honoraria for research, consultation, lectures, and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire, and TEVA ratiopharm. Christian Enzinger received funding for travel and speaker honoraria from Biogen, Bayer, Celgene, Merck, Novartis, Roche, Shire, Sanofi-Genzyme, and Teva Pharmaceutical Industries Ltd./sanofi-aventis, research support from Merck Serono, Biogen, Sanofi-Genzyme, and Teva Pharmaceutical Industries Ltd./sanofi-aventis and serving on scientific advisory boards for Bayer Schering, Biogen, Merck Serono, Novartis, Roche, and Teva Pharmaceutical Industries Ltd./sanofi-aventis. Fritz Leutmezer has received funding for travel and speaker honoraria from Biogen, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme, Santhera, and Teva Pharmaceutical Industries Ltd./sanofi-aventis. Jörg Kraus received consulting and/or research funding and/or educational support from Almirall, Bayer, Biogen, Celgene, MedDay, Medtronic, Merck, Novartis, Roche, Sanofi-Aventis, Shire, TEVA ratiopharm. Stefan Kalcher declares that there is no conflict of interest. Erich Kvas declares that there is no conflict of interest. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Bayer, Biogen, Biologix, Bionorica, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, TG Pharmaceuticals, TEVA-ratiopharm, and UCB. His institution has received financial support in the last 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi/Genzyme, and TEVA ratiopharm) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, and TEVA.
: The AMSTR is compliant with Austrian laws on bioethics and it was also approved by the ethical committee of the Medical University of Vienna (EC number 2096/2013).